Skip to main content

Table 6 Outcomes at 2 h after second dose of study drug for the rescue population

From: Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN)

FIRST DOSE

Lasmiditan 50 mg

Lasmiditan 100 mg

Lasmiditan 200 mg

SECOND DOSE

Placebo

Lasmiditan 50 mg

Placebo

Lasmiditan 100 mg

Placebo

Lasmiditan 200 mg

Pain free, n/N (%)

18/79 (23%)

33/166 (20%)

31/125 (25%)

67/262 (26%)

27/103 (26%)

59/207 (29%)

MBS free, n/N (%)

23/69 (33%)

52/142 (37%)

36/109 (33%)

74/221 (34%)

34/90 (38%)

65/182 (36%)

Pain relief, n/N (%)

36/79 (46%)

75/166 (45%)

60/125 (48%)

121/262 (46%)

49/103 (48%)

101/207 (49%)

  1. Abbreviation: MBS most bothersome symptoms